Aarti Drugs (524348) AGM 2024 presentation summary

Key milestones and business overview

• Incorporated in 1984, with major amalgamations in 1996 and listed on BSE (1993) and NSE (2003).

• Achieved consolidated revenue of over Rs. 2,500 crore in 2024, with significant growth milestones in 1998, 2014, and 2021.

• Operates 13 manufacturing facilities with a monthly capacity of 4,765 MT and presence in 100+ countries.

• Largest global producer of several APIs, including Metronidazole, Nimesulide, and Ketoconazole.

• Employs around 1,749 people, with export revenue contributing ~38%.

Diversified operations and manufacturing

• API segment contributes ~92% of revenues, with 50+ molecules produced and 9 manufacturing units.

• Formulation business operates via a subsidiary, with a WHO-GMP approved plant and 3 billion tablets capacity.

• Specialty chemicals and intermediates segment has 3 units, with backward integration supporting cost efficiency.

• Facilities hold multiple international accreditations (WHO-GMP, EUGMP, USFDA, etc.).

• Installed capacity increased from 48,920 MT in FY22 to 57,179 MT in FY24.

R&D and innovation

• R&D spend in FY24 was ~Rs. 20 crore, with centers in Tarapur and Turbhe.

• Developed 30+ APIs in the last 5 years and focuses on complex generics for regulated and emerging markets.

• Plans to expand into complex semi-solids and oral liquids for global markets.

• R&D recognized by DSIR, with strong academic collaborations.